It’s a two-fer for McCann Health. The agency won Cannes Lions Health network advertising agency of the year for the second year in a row.

Shire nabbed FDA approval Wednesday for its new long-acting ADHD drug Mydayis, and it's targeting $500 million in sales by 2020.

Mylan, which already has a low tax rate by being based in the Netherlands, has cut it into the single digits by investing in refined coal plants.

After scoring impressive numbers with its science-focused TV ad, Pfizer is preparing to launch another next month starring one of its own scientists.

An FDA committee backed a cardiovascular risks indication for Novo's Victoza on Tuesday.

Analysts with Evaluate predict GlaxoSmithKline's Bexsero and Shingrix will quickly grow sales in the coming years.

There’s a new FDA-approved ADHD medication on the scene, and it’s one maker Neos Therapeutics thinks will put it in prime market position.

Declining sales of Prevnar have urged Pfizer to seek compensation elsewhere, including a vaccine against Group B streptococcus.